Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2

Molecular and Biochemical Parasitology

Volumn 130, Issue 2, 2003, Pages 65-74

  Becker, Ingeborg ^a   Salaiza, Norma ^a   Aguirre, Magdalena ^a   Delgado, José ^a   Carrillo Carrasco, Nuria ^a   Kobeh, Laila Gutiérrez ^a   Ruiz, Adriana ^a   Cervantes, Rocely ^a   Torres, Armando Pérez ^a   Cabrera, Nallely ^b   González, Augusto ^a   Maldonado, Carmen ^c   Isibasi, Armando ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Cytokines; Innate immunity; Leishmania major; TLR 2

Indexed keywords

CARBOHYDRATE; CYTOKINE; GAMMA INTERFERON; GLYCAN; GLYCOCONJUGATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; LIPOPHOSPHOGLYCAN; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; CARBOHYDRATE ANALYSIS; CELL ACTIVATION; CELL MEMBRANE; CELL STIMULATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LEISHMANIA; NATURAL KILLER CELL; NUCLEOCYTOPLASMIC TRANSPORT; PARASITE DEVELOPMENT; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; PURIFICATION; RECEPTOR BINDING; REGULATORY MECHANISM; UPREGULATION;

LEISHMANIA MAJOR;

EID: 17144437953     PISSN: 01666851     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-6851(03)00160-9     Document Type: Article

References (52)

1. Medzhitov R., Janeway C.A. Jr. Innate immunity: impact on the adaptive immune response. Curr. Op. Immunol. 9:1997;4-9.
2. Medzhitov R., Janeway C.A. Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 91:1997;295-298.
3. Campos M., Almeida I., Takeuchi O., Akira S., Valente E., Procopio D.et al. Activation of toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J. Immunol. 167:2001;416-423.
4. Ferguson M. The structure, biogenesis and functions of glucosylphosphatidylinositol anchors, and the contributions of trypanosome research. J. Cell. Sci. 112:1999;2799-2809.
5. McConville M.J., Ferguson M.A. The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes. Biochem. J. 294:1993;305-324.
6. McConville M.J., Schnur L.F., Jaffe C., Schneider P. Structure of Leishmania lipophosphoglycan: inter- and intra-specific polymorphism in Old World species. Biochem. J. 310:1995;807-818.
7. Handman E. Leishmania virulence: it's a knock out. Trends Parasitol. 17:2001;60.
8. Turco S.J., Descoteaux A. The lipophosphoglycan of Leishmania parasites. Ann. Rev. Microbiol. 46:1992;65-94.
9. Sacks D.L., Modi G., Rowton E., Späth G., Epstein L., Turco S.J.et al. The role of phosphoglycans in Leishmania-sand fly interactions. Proc. Natl. Acad. Sci. USA. 97:2000;406-411.
10. Moll H. Epidermal Langerhans cells are critical for immunoregulation of cutaneous leishmaniasis. Immunol. Today. 14:1993;383-387.
11. Maasho K., Sanchez F., Schurr E., Hailu A., Akuffo H. Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity. Infect. Immun. 66:1998;2698-2704.
12. Scott P., Trinchieri G. The role of natural killer cells in host-parasite interactions. Curr. Opin. Immunol. 7:1995;34-40.
13. Vester B., Muller K., Solbach W., Laskay T. Early gene expression of NK cell-activating chemokines in mice resistant to Leishmania major. Infect. Immun. 67:1999;3155-3159.
14. Laskay T., Diefenbach A., Röllinghoff M., Solbach W. Early parasite containment is decisive for resistance to Leishmania major infection. Eur. J. Immunol. 25:1995;2220-2227.
15. Lanier L.L. Turning on natural killer cells. J. Exp. Med. 191:2000;1259-1262.
16. Stepp S.E., Mathew P.A., Bennett M., De Saint Basile G., Kumar V. Perforin: more than just an effector molecule. Immunol. Today. 21:2000;254-256.
17. Moretta L., Biassoni R., Bottino C., Mingari M.C., Moretta A. Human NK-cell receptors. Immunol. Today. 21:2000;420-422.
18. Akuffo H., Maasho K., Howe R. Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through stimulation of natural killer (NK) cells. Clin. Exp. Immunol. 94:1993;516-521.
19. Barral-Netto M., Barral A., Brodskyn C., Carvalho E.M., Reed S.G. Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol. 17:1995;21-28.
20. Nylen S., Maasho K., Soderstrom K., Ilg T., Akuffo H. Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin. Exp. Immunol. 131:2003;457-467.
21. Sacks D.L., Hieny S., Sher A. Identification of cell surface carbohydrate and antigenic changes between non-infective and infective developmental stages of Leishmania major promastigotes. J. Immunol. 135:1985;564-569.
22. McConville M.J., Bacic A., Mitchell G.F., Handman E. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc. Natl. Acad. Sci. USA. 84:1987;8941-8945.
23. Kirschning C.J., Wesche H., Ayres T.M., Rothe M. Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J. Exp. Med. 188:1998;2091-2097.
24. Santana M.A., Pedraza-Alva G., Olivares-Zavaleta N., Madrid-Marina V., Horejsi V., Burakoff S.J.et al. CD43-mediated signals induce DNA binding activity of AP-1, NF-AT, and NFκB transcription factors in human T lymphocytes. J. Biol. Chem. 275:2000;31460-31468.
25. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
26. McConville M.J., Turco S.J., Ferguson M.A., Sacks D.L. Developmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage. EMBO J. 11:1992;3593-3600.
27. Sacks D.L., Brodin T., Turco S.J. Developmental modification of the lipophosphoglycan from Leishmania major promastigotes during metacyclogenesis. Mol. Biochem. Parasitol. 42:1990;225-233.
28. Kelleher M., Bacic A., Handman E. Identification of a macrophage-binding determinant on lipophosphoglycan from Leishmania major promastigotes. Proc. Natl. Acad. Sci. USA. 89:1992;6-10.
29. Wilhelm P., Ritter U., Labbow S., Donhauser N., Röllinghoff M., Bogdan C.et al. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J. Immunol. 166:2001;4012-4019.
30. Liew F.Y., Li Y., Millot S. Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunology. 71:1990;556-559.
31. Bogdan C., Moll H., Solbach W., Röllinghoff M. Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur. J. Immunol. 20:1990;1131-1135.
32. Proudfoot L., Nikolaev A.V., Feng G.J., Wei X.Q., Ferguson M.A.J., Brimacombe J.S.et al. Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages. Proc. Natl. Acad. Sci. USA. 93:1996;10984-10989.
33. Brittingham A., Mosser D.M. Exploitation of the complement system by Leishmania promastigotes. Parasitol. Today. 12:1996;444-447.
34. β gene expression in human monocytes via a unique promoter sequence. Proc. Natl. Acad. Sci. USA. 93:1996;14708-14713.
35. Carrera L., Gazzinelli R.T., Badolato R., Hieny S., Muller W., Kuhn R.et al. Leishmania promastigotes selectively inhibits interleukin-12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J. Exp. Med. 183:1996;515-526.
36. Sutterwala F.S., Mosser D.M. The taming of IL-12: suppressing the production of proinflammatory cytokines. J. Leukoc. Biol. 65:1999;543-551.
37. Lo S.K., Bovis L., Matura R., Zhu B., He S., Lum H.et al. Leishmania lipophosphoglycan reduces monocyte transendothelial migration: modulation of cell adhesion molecules, intercellular junctional proteins and chemoattractants. J. Immunol. 160:1998;1857-1865.
38. Ponte-Sucre A., Heise D., Moll H. Leishmania major lipophosphoglycan modulates the phenotype and inhibits migration of murine Langerhans cells. Immunology. 104:2001;462-467.
39. Talamas-Rohana P., Wright S.D., Lennartz M.R., Russell D.G. Lipophosphoglycan from Leishmania mexicana promastigotes binds to members of the CR3, p150, 95 and LFA-1 family of leukocyte integrins. J. Immunol. 144:1990;4817-4824.
40. Rosenthal L.A., Sutterwala F.S., Kehrli M.E., Mosser D.M. Leishmania major-human macrophage interactions: cooperation between Mac-1 (CD11b/CD18) and complement receptor type 1 (CD35) in promastigote adhesion. Infect. Immun. 64:1996;2206-2215.
41. Desjardins M., Descoteaux A. Inhibition of phagolysosomal biogenesis by the Leishmania lipophosphoglycan. J. Exp. Med. 185:1997;2061-2068.
42. Descoteaux A., Matlashewski G., Turco S. Inhibition of macrophage protein kinase C-mediated protein phosphorylation by Leishmania donovani lipophosphoglycan. J. Immunol. 149:1992;3008-3015.
43. Descoteaux A., Turco S.J., Sacks D.L., Matlashewski G. Leishmania donovani lipophosphoglycan selectively inhibits signal transduction in macrophages. J. Immunol. 146:1991;2747-2753.
44. Muzio M., Bosisio D., Polentarutti N., D'amico G., Stoppacciaro A., Mancinelli R.et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 164:2000;5998-6004.
45. Flo T.H., Halaas O., Torp S., Ryan L., Lien E., Dybdahl B.et al. Differential expression of toll-like receptor 2 in human cells. J. Leukoc. Biol. 69:2001;474-481.
46. Wang T., Lafuse W.P., Zwilling B.S. Regulation of toll-like receptor 2 expression by macrophages following Mycobacterium avium infection. J. Immunol. 165:2000;6308-6313.
47. Salaiza Suazo N., Volkow P., Pérez Tamayo R., Moll H., Gillitzer R., Pérez-Torres A.et al. Treatment of patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. Trop. Med. Int. Health. 4:1999;801-811.
48. Ritter U., Moll H., Laskay T., Bröcker E.B., Velazco O., Becker I. et al. Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis. J. Infect. Dis. 173:1996;699-709.
49. Cáceres-Dittmar G., Tapia F.J., Sánchez M.A., Yamamura M., Uyemura K., Modlin R.L.et al. Determination of the cytokine profile in American cutaneous leishmaniasis using polymerase chain reaction. Clin. Exp. Immunol. 91:1993;500-505.
50. Melby P.C., Andrade-Narvaez F.J., Darnell B.J., Valencia-Pacheco G., Tryon V.V., Palomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 62:1994;837-842.
51. Qadoumi M., Becker I., Donhauser N., Röllinghoff M., Bogdan C. Expression of inducible nitric oxide synthase in skin lesions of patients with American cutaneous leishmaniasis. Infect. Immun. 70:2002;4638-4642.
52. Diefenbach A., Schindler H., Röllinghoff M., Yokoyama W.M., Bogdan C. Requirement for type 2 NO synthase for IL-12 signalling in innate immunity. Science. 284:1999;951-955.